2. Search Result
Search Result
Results for "

theranostic

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

4

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3441A
    3BP-4089 TFA

    		FAP Cancer
    3BP-4089 TFA is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 TFA is often coupled with radionuclides for tumor diagnosis and research .
    3BP-4089 TFA
  • HY-147057
    Rofapitide tetraxetan
    4 Publications Verification

    FAP-2286

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
    Rofapitide tetraxetan
  • HY-155485
    Abi-DZ-1

    		Others Cancer
    Abi-DZ-1 is a potential multifunctional theranostic agent via the HIF1α/OATPs Pathway. Abi-DZ-1 can be used in the research of tumor-targeted imaging and precision therapy .
    Abi-DZ-1
  • HY-142533
    HL-PEG2k

    		Biochemical Assay Reagents Cancer
    HL-PEG2k is a second near-infrared Ru(II) polypyridyl complex. HL-PEG2k exhibits a wavelength bathochromic shift, enhanced photothermal conversion efficiency (41.77%), and an antineoplastic effect against glioma. HL-PEG2k displays a superior biocompatibility and thus can be a potential theranostic platform to combat the growth and recurrence of tumors .
    HL-PEG2k
  • HY-155278
    Anticancer agent 162

    		Others Cancer
    Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity .
    Anticancer agent 162
  • HY-P3441
    3BP-4089

    		FAP Cancer
    3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research .
    3BP-4089
  • HY-P10648
    Herceptide

    HER2-targeting peptide

    		 EGFR Cancer
    Herceptide (HER2-targeting peptide) is a HER2-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .
    Herceptide
  • HY-163077
    Anticancer agent 175

    		Reactive Oxygen Species (ROS) Apoptosis Cancer
    Anticancer agent 175 (complex 1) ia a near-infrared (NIR) luminescent theranostic complex. Anticancer agent 175 induces ROS accumulation, mitochondrial damage, disruption of Bax/Bcl-2 equilibrium, and tumor cell apoptosis in HepG2 cell line .
    Anticancer agent 175
  • HY-155070
    SRE-II

    		DNA/RNA Synthesis Apoptosis Cancer
    SRE-II, an amide derivative, is an activatable photosensitizer for photodynamic cancer research with decreased fluorescence and photosensitizing capabilities. SRE-II can be further converted into the active photosensitizer SDU Red via carboxylesterase-catalyzed amide bond cleavage. SRE-II induces DNA damage and cell apoptosis in the presence of light. SRE-II can act as a promising theranostic agent for triple-negative breast cancer .
    SRE-II
  • HY-P11261
    AAZTA-NI-PSMA-093

    		PSMA Cancer
    AAZTA-NI-PSMA-093 is a bispecific agent targeting prostate-specific membrane antigen (PSMA) with an IC50 value for PSMA of 87.48 nM. AAZTA-NI-PSMA-093 has a PSMA targeting module and an oxygen-sensitivity module (hypoxia-sensitive NI-moiety). AAZTA-NI-PSMA-093 can utilize the PSMA targeting property as a "navigation system" to efficiently concentrate the entire molecule within prostate cancer cells, and once the cells are in an oxygen-deficient state, the molecule will irreversibly capture and remain in the oxygen-deficient cells, achieving "secondary enrichment". AAZTA-NI-PSMA-093 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu, and has high accumulation and rapid clearance characteristics in mouse models. AAZTA-NI-PSMA-093 can be used for the study of prostate cancer .
    AAZTA-NI-PSMA-093
  • HY-178819
    NM-001

    		Integrin Drug Intermediate Cancer
    NM-001 is a theranostic prodrug that targets ανβ3 integrin. NM-001 consists of cRGD and GFLG peptides, a DCM fluorophore and Chlorambucil (HY-13593). NM-001 internalizes into lysosomes of tumor cells via the cRGD peptide, and generates NM-002 (HY-178820) and Chlorambucil through intracellular cleavage at the GFLG peptide by overexpressed Cathepsin B (CTSB). NM-001 exhibits green fluorescence under physiological conditions, and converts to NIR fluorescence by CTSB activation. NM-001 has significant antitumor activity with low toxicity in HeLa cell xenografts mouse models. NM-001 can be used for real-time drug release monitoring research .
    NM-001
  • HY-75706
    N-Descyclopropanecarbaldehyde Olaparib

    		PARP Ligands for Target Protein for PROTAC Cancer
    N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
    N-Descyclopropanecarbaldehyde Olaparib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: